Related Experiment Video

Updated: Jun 24, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

The Effect of Omega-3 Supplementation on Heart Failure Outcome: A Meta-Analysis of Randomized Clinical Trial

Bambang Dwiputra1, Ade Meidian Ambari1, Dwita Rian Desandri1

  • 1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia - Harapan Kita National Cardiovascular Center, DKI Jakarta, Indonesia.

Journal of Lipid and Atherosclerosis
|June 3, 2024
PubMed

Insights

Omega-3 supplementation does not significantly reduce cardiovascular mortality or heart failure hospitalizations. This meta-analysis found no beneficial effect for omega-3s in heart failure patients.

Area of Science:

  • Cardiology
  • Nutritional Science
  • Clinical Trials

Background:

  • Omega-3 fatty acid supplementation's impact on cardiovascular disease is well-researched.
  • Evidence regarding its efficacy in heart failure (HF) patients remains inconclusive.

Purpose of the Study:

  • To conduct a meta-analysis assessing the effects of omega-3 supplementation on cardiovascular mortality and HF hospitalizations.
  • To clarify the role of omega-3s in managing patients with heart failure.

Main Methods:

  • A comprehensive literature search was performed across MEDLINE, Embase, and Cochrane databases.
  • Included clinical trials and preprints underwent critical appraisal.
  • Data from 5 selected studies were pooled for meta-analysis.

Main Results:

  • Omega-3 supplementation showed no significant association with reduced cardiovascular mortality (OR, 0.94; 95% CI, 0.84-1.05; p=0.16).
  • No significant reduction in heart failure hospitalizations was observed (OR, 0.94; 95% CI, 0.88-1.02; p=0.13).

Conclusions:

  • This systematic review and meta-analysis indicates that omega-3 supplementation offers no discernible benefit for patients diagnosed with heart failure.
  • Current evidence does not support the use of omega-3s to improve outcomes in heart failure management.

Keywords:
AtherosclerosisCardiovascular diseaseOmega-3 fatty acidSecondary prevention

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.5K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570